

**New Jersey Drug Utilization Review Board
Virtual Platform
July 15, 2026**

<https://nj.gov/humanservices/dmahs/public-advisory/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for April 15, 2026, meeting
https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/DURB_Transcript_April_2026_Final.pdf
- IV. Review of draft meeting summary for April 15, 2026, meeting (pages 3-6)
- V. Secretary's report (page 7)
- VI. Old Business
 - A. Utilization Trends of GLP-1/GIP Agonists (pages 8-9)
 - B. Utilization Trends of SGLT-2 Inhibitors (pages 10-11)
- VII. New Business
 - A. Proposed Addendum to Protocol for Gattex[®] (pages 12-13)
 - B. Proposed Addendum to Protocol for Strensiq[®] (pages 14-16)
 - C. Proposed Protocol for C Type Natriuretic Peptide Products (pages 17-18)
 - D. Protocols to be Retired (page 19)

VIII. A. Informational Highlights/Reports

1. Gainwell Technologies/NJ MCO 1st Quarter 2026 Prior Authorization Report
2. (page 20)
3. Summary of DURB Action Items (pages 21-24)
4. DHS/DOH Pharmacy Programs Top Drugs Report/Physicians Administered Drugs Report (by amount paid and by category):

FFS top drugs:

[https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/FFS_Top_Drugs_Report_\(March-2026\)_ALL.pdf](https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/FFS_Top_Drugs_Report_(March-2026)_ALL.pdf)

MCO top drugs:

[https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/MCO_Top_Drugs_Report_\(March-2026\)_by_Payment.pdf](https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/MCO_Top_Drugs_Report_(March-2026)_by_Payment.pdf)

FFS top drugs by category:

[https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/FFS_Top_Drugs_by_Category_\(March-2026\)_by_Payment.pdf](https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/FFS_Top_Drugs_by_Category_(March-2026)_by_Payment.pdf)

MCO top drugs by category:

[https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/MCO_Top_Drugs_by_Category_\(March-2026\)_by_Payment.pdf](https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/MCO_Top_Drugs_by_Category_(March-2026)_by_Payment.pdf)

FFS antiviral drugs:

[https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/FFS_Antiviral_Drugs_\(March-2026\)_by_Payment.pdf](https://www.nj.gov/humanservices/dmahs/documents/boards/durb/agendas/7-2026/FFS_Antiviral_Drugs_(March-2026)_by_Payment.pdf)

B. Recent Updates

KDIGO 2026 Clinical Practice Guideline for Diabetes and Chronic Kidney Disease (CKD)

<https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-Diabetes-and-CKD-Guideline-Update-Public-Review-Draft-March-2026.pdf>

Guidelines of care for the management of atopic dermatitis in pediatric patients

<https://www.jaad.org/action/showPdf?pii=S0190-9622%2826%2900343-9>

Relationship between menopausal hormone therapy and incidence of breast cancer: systemic review and meta-analysis

https://pmc.ncbi.nlm.nih.gov/articles/PMC12981265/pdf/IANN_58_2640244.pdf

American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes – 2026 Update

<https://www.endocrinepractice.org/action/showPdf?pii=S1530-891X%2826%2900022-4>